Thomas W. Beetham is CLO & VP at Kiniksa Pharmaceuticals, Ltd. (KNSA). They have made 6 open-market trades across 3 companies since 2018, most recently 2026-03-03.
CIK 0001741382
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $117K since 2018, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VRDN | BUY | 2024-09-27 | 2024-09-30 | $23.41 | $117K | -10.0% | -9.3% | -20.0% |
| MGTA | SELL | 2021-09-16 | 2021-09-20 | $6.73 | $41K | -1.6% | -11.5% | -31.6% |
| KNSA | SELL | 2021-02-03 | 2021-02-05 | $22.09 | $109K | +11.5% | +0.8% | -31.8% |
| KNSA | SELL | 2020-07-01 | 2020-07-02 | $25.37 | $1.5M | -7.3% | -18.9% | -36.8% |
| KNSA | SELL | 2020-06-10 | 2020-06-12 | $25.07 | $690K | +15.6% | -0.4% | -27.4% |
| KNSA | SELL | 2020-04-20 | 2020-04-22 | $19.08 | $1.9M | -2.2% | +5.1% | +6.2% |
| KNSA | SELL · 10b5-1 | 2020-02-14 | 2020-02-19 | $18.58 | $1K | +3.2% | -28.4% | +8.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.